{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"73","value":"49"},{"groupId":"OG001","lowerLimit":"40","upperLimit":"72","value":"52"},{"groupId":"OG002","lowerLimit":"33","upperLimit":"86","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"The Overall Survival is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease and are still alive","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"OG000","title":"Soft Tissue Sarcoma"},{"description":"Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma \\[de-differentiated or mesenchymal\\]. Pembrolizumab was administered at 200 mg intravenously every 3 weeks\n\nPembrolizumab","id":"OG001","title":"Bone Sarcoma"},{"description":"Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks","id":"OG002","title":"Expansion Cohort"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"weeks"}